Nanopublications

@prefix dcterms: <http://purl.org/dc/terms/> .
@prefix this: <http://bio2rdf.org/drugbank_resource:DB01045_DB01242_nanopub.RA1LwLMFQmMoEwRpON_N3dRc7qxHkXGxZUHbtgKeFr4Fw> .
@prefix sub: <http://bio2rdf.org/drugbank_resource:DB01045_DB01242_nanopub.RA1LwLMFQmMoEwRpON_N3dRc7qxHkXGxZUHbtgKeFr4Fw#> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix pav: <http://purl.org/pav/> .
@prefix orcid: <http://orcid.org/> .
@prefix codebase: <https://github.com/tkuhn/bio2rdf2nanopub> .
@prefix version: <https://github.com/tkuhn/bio2rdf2nanopub/tree/eda7951a5f6c622c5d2132f50c3093138484a349> .
@prefix instance: <https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB> .
@prefix process: <https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB.3c184e6c-ceb8-4275-a679-71dfbdac2a11> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix has-source: <http://semanticscience.org/resource/SIO_000253> .
@prefix d: <http://bio2rdf.org/drugbank:> .
@prefix dv: <http://bio2rdf.org/drugbank_vocabulary:> .
@prefix dr: <http://bio2rdf.org/drugbank_resource:> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:head {
  this: np:hasAssertion sub:assertion ;
    np:hasProvenance sub:provenance ;
    np:hasPublicationInfo sub:publicationInfo ;
    a np:Nanopublication .
}

sub:assertion {
  d:DB01045 dv:ddi-interactor-in dr:DB01045_DB01242 .
  d:DB01242 dv:ddi-interactor-in dr:DB01045_DB01242 .
  dr:DB01045_DB01242 dcterms:identifier "drugbank_resource:DB01045_DB01242" ;
    dcterms:title "DDI between Rifampicin and Clomipramine - The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, clomipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of clomipramine if rifampin is initiated, discontinued or dose changed."@en ;
    a dv:Drug-Drug-Interaction ;
    rdfs:label "DDI between Rifampicin and Clomipramine - The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, clomipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of clomipramine if rifampin is initiated, discontinued or dose changed. [drugbank_resource:DB01045_DB01242]"@en .
}

sub:provenance {
sub:assertion has-source: dr:bio2rdf.dataset.drugbank.R3 .
}

sub:publicationInfo {
  sub:signature.MCwCFBLTCY2qSR0A npx:hasPublicKey "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" ;
    npx:hasSignature "MCwCFBLTCY2qSR0AawgQH9SmwubzKbpPAhRzwU9t6n7lEmyt9UcrnC3nHsQerw==" ;
    npx:signedBy instance: .
  this: dcterms:created "2018-03-30T11:12:27.227+02:00"^^xsd:dateTime ;
    dcterms:license <https://creativecommons.org/licenses/by-nc/4.0/> ;
    npx:hasSignatureElement sub:signature.MCwCFBLTCY2qSR0A ;
    prov:wasGeneratedBy process: .
  instance: prov:specializationOf codebase: ;
    prov:wasAttributedTo orcid:0000-0002-1267-0234 .
  process: dcterms:identifier "3c184e6c-ceb8-4275-a679-71dfbdac2a11" ;
    prov:used version: ;
    prov:wasAssociatedWith instance: ;
    prov:wasStartedBy orcid:0000-0002-1267-0234 .
  version: dcterms:isVersionOf codebase: ;
    pav:version "eda7951a5f6c622c5d2132f50c3093138484a349" ;
    prov:wasAttributedTo orcid:0000-0002-1267-0234 .
}